MedTrace Logo

Bioavailability Study of Torsemide Tablets Under Fed Conditions

NCT00654043 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2008-04-11

No results posted yet for this study

Summary

To compare the single-dose bioavailability of Torsemide tablets with Demadex

Conditions

  • Healthy

Interventions

DRUG

Torsemide

tablets, 20 Mg, single-dose

DRUG

Demadex

Tablets, 20 mg, single-dose

Sponsors & Collaborators

  • Anapharm

    collaborator INDUSTRY

  • Par Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Eric Masson · Anapharm

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-04-30
Primary Completion
2001-05-31
Completion
2001-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00654043 on ClinicalTrials.gov